Navigation Links
S*BIO Expands Pipeline With the Development of a Unique Flt3 -CDK Inhibitor as a Targeted Therapy for Acute Leukemias
Date:11/27/2007

SINGAPORE, Nov. 27 /PRNewswire/ -- S*BIO Pte Ltd today announced the expansion of its proprietary pipeline, with its third development candidate, SB1317. This is a novel orally-available small molecule compound targeted for the treatment of acute leukemias.

SB1317 is designed to selectively inhibit major signalling pathways involving Flt3 and CDK, which impact disease progression in acute leukemias. Flt3 mutations are the most frequent genetic alterations reported in acute myeloid leukemia (AML) patients and are associated with a poor prognosis. In addition, over-expression of wild type Flt3 has been found in acute lymphoblastic leukemia (ALL) patients. Cyclin-dependent kinases or CDKs play important roles in cell cycle control. By inhibiting both Flt3 and CDK kinases, SB1317 is uniquely positioned as a "first-in-class" compound to treat relapsed and refractory acute leukemias. SB1317 has already entered preclinical development.

"The ability to maintain long-term control in AML and ALL remains one of the most significant unmet medical needs in the adult leukemia market. SB1317 has been designed with this in mind, and we believe it has the potential to become a first of its kind Flt3 inhibitor to specifically target this group of patients," said Dr. Jan-Anders Karlsson, CEO of S*BIO, "With its ideal profile for treating relapsed and refractory AML and ALL, SB1317 provides an opportunity for S*BIO to expand its portfolio of new targeted therapies for hematological disorders."

Approximately 300,000 new cases of leukemia are diagnosed worldwide each year, and there are about 36,000 new cases of acute leukemia in the seven major pharmaceutical markets*. Acute leukemia is characterized by rapid growth and accumulation of immature blood cells in the bone marrow. This results in fewer normal blood cells. Relapse rates following conventional leukemia treatments remain high and limited treatment options exist for patients who relapse after standard induction and post-remission chemotherapy. The 5 year overall survival rate for elderly patients with AML is 5-15% and about 30% in younger adults*.

About S*BIO Pte Ltd

S*BIO is a privately-held biotech company focused on the research and clinical development of novel targeted small molecule drugs for the treatment of cancer with leading programs around histone deacetylases (HDAC) and kinases. Its lead candidate, SB939, has entered the clinic in 2Q 2007. It recently announced that a second compound, SB1518, would enter the clinic in 1H 2008.

In line with its vision to be a leading fully-integrated oncology-focused biotech company in Asia Pacific, S*BIO has established a state-of-the-art R&D infrastructure, complemented by a strong clinical development team. S*BIO has strong linkages with a network of medical oncologists in Asia Pacific and its investors include Bio*One Capital, Novartis Bioventures and other international funds. More information about S*BIO can be found at http://www.sbio.com.

S*BIO Pte Ltd:

Stephen Keith Rhind, Ph.D.

Senior Vice President, Corporate Development

Tel: +65 6827 5000 (Singapore)

Stephen_rhind@sbio.com

Russo Partners:

Tony Russo +1 212-845-4251

Tony.Russo@russopartnersllc.com

Andreas Marathovouniotis +1 212-845-4253

Andreas.Marathis@russopartnersllc.com

*source: Datamonitor


'/>"/>
SOURCE S*BIO Pte Ltd
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Longaberger Expands Horizon of Hope Campaign to Build Support for American Cancer Societys Breast Cancer Initiatives
2. Rohm and Haas Expands in India
3. US Med-Equip Expands Corporate Support Center
4. Concentra Expands Horizon Air Employee Health Program With On-Site Clinic
5. Regional Center of Orange County Expands Family Support Resources to Meet Growing Needs
6. Maimonides Expands Circulation of Physicians Practice Journal to Staten Island Doctors
7. Specialty Blades, Inc. Expands Management Team With New VP Engineering
8. CRH Medical expands Las Vegas operations
9. ISTA Pharmaceuticals Expands Its Pipeline in Allergy Treatments
10. Bipartisan Bill Expands Health Care Access for Small Businesses
11. ABR-Affinity BioReagents Expands 100% Quality Guarantee
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... , ... The International Association of Eating Disorders Professionals (iaedp) announces the 2017 ... image mannequin art competition. Selected from 15 submissions from around the nation, the top ... 31st annual iaedp Symposium, March 22 – 26 in Las Vegas. , This year, ...
(Date:2/24/2017)... Farifax, VA (PRWEB) , ... February 24, 2017 , ... ... winners for excellence in radiology marketing programs at the annual Building Better ... the Worthington Renaissance Fort Worth Hotel in Fort Worth, Texas. Nine awards are given ...
(Date:2/24/2017)... ... February 24, 2017 , ... Congratulations ... International Elite division on February 12th. Ms. Esparza qualified into this prestigious ... qualifier competition held in Las Vegas, Nevada. Frida is one of approximately 25 ...
(Date:2/23/2017)... ... 23, 2017 , ... Thinksport, the most award-winning sunscreen on ... of Marin. For the second year in a row, cyclists will stay protected ... are thrilled to provide our safe, non-toxic sunscreen to over 2,000 cycling enthusiasts ...
(Date:2/23/2017)... ... February 23, 2017 , ... The 89th Academy Awards will be celebrated ... National Education Policy Center Bunkum Award. We invite you to enjoy our 11th annual ... Bunkum winner is the Center for American Progress (CAP), for its report, Lessons From ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... , Feb. 23, 2017  Cogentix Medical, Inc. ... and markets innovative proprietary products for the urology market, ... fiscal year ended December 31, 2016 before the market ... The Company will host a conference call and webcast ... Thursday, March 9, 2017 at 11:00 a.m. Eastern Time ...
(Date:2/23/2017)... 23, 2017 Nevro Corp. (NYSE: NVRO), a global ... the treatment of chronic pain, today reported financial results for ... 2016 Accomplishment & Highlights: ... an increase of 228% as reported, over the prior year ... increase of 612% over the prior year ...
(Date:2/23/2017)... , 23. Februar 2017 Im Rahmen ... nationale Wirtschaftszone in der südwestlichen chinesischen Provinz Guizhou, 2017 mit ... einer Innovationsplattform aktiv an der Entwicklung einer eingebetteten Hightech-Schlüsselindustrie. ... Continue Reading ... ...
Breaking Medicine Technology: